Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Survival with liver transplant in primary biliary cirrhosis is high

The latest Clinical Transplantation shows excellent survival rates with 15 years follow-up after liver transplantation in primary biliary cirrhosis, and that recipient's age, and tacrolimus immunosuppression are risk factors recurrence.

News image

fiogf49gjkf04

Orthotopic liver transplantation is the only effective curative therapy for end-stage primary biliary cirrhosis.

Survival after orthotopic liver transplantation is excellent.

However, recent data have shown a recurrence rate of primary biliary cirrhosis of up to 32% after transplantation.

Dr Dietmar Jacoba and colleagues from Germany investigated the course after disease recurrence.

The researchers particularly assessed liver function and survival with long-term follow-up.

The team performed 1553 liver transplantations in 1415 patients at the Charité, Virchow Clinic, between 1989 and 2003.

Protocol liver biopsies were taken after 1, 3, 5, 7, 10 and 13 years.

The team reported that 7% of patients suffered from histologically proven primary biliary cirrhosis.

Patient survival after 15 years was 82%
Clinical Transplantation

Primary immunosuppression consisted of cyclosporine or tacrolimus.

Immediately after orthotopic liver transplantation, all patients received ursodeoxycholic acid.

The research team withdrew corticosteroids 3 to 6 months after orthotopic liver transplantation.

The team noted that the median age of the 85 women and 15 men was 55 years.

The median follow-up after liver transplantation was 118 months, and 30 months after recurrence 30 months.

The researchers found that actuarial patient survival after 5, 10 and 15 years was 87%, 84% and 82% respectively.

The team reported that 10% of patients died after a median survival time of 32 months.

Of the patients that died, 2 developed organ dysfunction owing to recurrence of primary biliary cirrhosis.

Histological recurrence was found in 14% of patients after a median time of 61 months.

The team observed that patients with tacrolimus immunosuppression developed primary biliary cirrhosis recurrence more often, and also earlier.

The research team identified 57 patients that developed an acute rejection, and 2 patients with a chronic rejection episode.

Liver function did not alter within the first 5 years after histologically proven primary biliary cirrhosis recurrence.

Dr Jacoba's team concluded, “Multivariate analysis of the investigated patients showed that the recipient's age and tacrolimus immunosuppression were significant risk factors for primary biliary cirrhosis recurrence.”

“Long-term follow-up of up to 15 years after liver transplantation, owing to primary biliary cirrhosis, in addition to maintenance of liver function, shows excellent organ and patient survival rates.”

“Although protocol liver biopsies revealed histological recurrence in 14% patients, only 2 patients developed graft dysfunction.”

“Tacrolimus-treated patients showed more frequently and also earlier histologically proven primary biliary cirrhosis recurrence.”

“However, in our population we could not observe an impact on graft dysfunction and patient's survival.”

Clin Transplant 2006:20(2):211
09 May 2006

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us